Genetic Alteration After Systemic Treatment in Breast Cancer

Inclusion Criteria

• •1. Patients older than 20 years
• •2. Patients with histologically confirmed breast cancer at three disease status
• •* Patients who are going to receive neoadjuvant chemotherapy with feasible biopsy site.
• •* Patients who recur from curative surgery and have distant metastasis with feasible biopsy site. ; Patients must have received adjuvant chemotherapy after curative surgery.
• •* Patients who are going to first-line palliative chemotherapy with feasible biopsy site.
• •3. Patients with PS ECOG 0 - 2
• •4. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
• •5. Written informed consent form
• •6. Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to study as defined below:
• •* Haemoglobin ≥9.0 g/L (transfusion allowed)
• •* White blood cells (WBC) \> 3 x 109/L
• •* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
• •* AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN